A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B

Tenofovir disoproxil fumarate (TDF) is one of the most widely used treatment options for human immunodeficiency virus (HIV) and HBV infections. Despite its efficacy and safety, some cases of nephrotoxicity have been reported in the treatment of HIV patients. Even more recently, very few cases of Fan...

Full description

Saved in:
Bibliographic Details
Published in:The Korean journal of gastroenterology Vol. 68; no. 6; p. 317
Main Authors: Kim, Dongwoo, Lee, Jongjin, Kim, Dae-ha, Kang, Kyuho, Suh, Sang Jun, Jung, Young Kul, Yim, Hyung Joon
Format: Journal Article
Language:Korean
Published: Korea (South) 25.12.2016
Subjects:
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Bone and Bones - diagnostic imaging
Calcifediol - analysis
Fanconi Syndrome - diagnosis
Fanconi Syndrome - etiology
Glomerular Filtration Rate
Hepatitis B, Chronic - drug therapy
Humans
Male
Middle Aged
Osteomalacia - diagnosis
Osteomalacia - etiology
Phosphates - metabolism
Renal Reabsorption
Tenofovir - adverse effects
Tenofovir - therapeutic use
Tenofovir
Hepatitis B virus
Fanconi syndrome
Osteomalacia
Kidney tubules, proximal
ISSN:1598-9992, 2233-6869
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tenofovir disoproxil fumarate (TDF) is one of the most widely used treatment options for human immunodeficiency virus (HIV) and HBV infections. Despite its efficacy and safety, some cases of nephrotoxicity have been reported in the treatment of HIV patients. Even more recently, very few cases of Fanconi syndrome associated with tenofovir therapy in HBV monoinfection have been reported. Herein, we report a case of a 47-year-old male with an HBV monoinfection, who developed Fanconi syndrome and a secondary osteomalacia with multiple bone pain. After TDF withdrawal and supplementation of calcitriol, his renal function was reverted. Although the overall risk of TDF-associated nephrotoxicity is very low, both glomerular and tubular function should be monitored in patients undergoing TDF treatment.
ISSN:1598-9992
2233-6869
DOI:10.4166/kjg.2016.68.6.317